Objective To determine the association of maternal substance use disorders (SUDs) during pregnancy with adverse neonatal outcomes and infant hospital re-admissions, observational stays, and emergency department utilization in the first year of life. the adjusted analysis, exposed neonates were more likely to be born preterm (aOR 1.85; 95% CI 1.75-1.96) and low birthweight (aOR 1.94; 95% CI 1.80-2.09). After controlling for maternal characteristics and preterm birth, SUDexposed neonates were more likely to have intrauterine growth restriction, cardiac, respiratory, neurologic, infectious, hematologic, and feeding/nutrition problems, prolonged hospital stay, and higher mortality (aOR range 1.26-3.80). Exposed infants were more likely to be rehospitalized (aOR 1.10; 95% CI 1.04-1.17) but less likely to have an observational stay (aOR 0.90; 95% CI 0.82-0.99) or use the emergency department (aOR 0.87; 95% CI 0.83-0.90) in the first year of life.
Although this prior analysis provided more accurate estimates of maternal SUDs and birth outcomes, infant health outcomes beyond the immediate perinatal period was not assessed. We move beyond this initial analysis with 3 additional years of data and include more detailed infant clinical health outcomes and utilization of hospital-based care up to the first year of life.
The objectives of this study were to determine the association of maternal SUDs during pregnancy with adverse neonatal outcomes (including NAS, prolonged newborn hospital stay, and medical complications such as respiratory problems, feeding difficulties, and neurologic problems) and to determine the association of maternal SUDs during pregnancy and infant hospital re-admissions, observational stays, and urgent care utilization in the first year of life.
Methods
The data sources for this study derive from a unique linkage of 2 Massachusetts (MA) population based data systems: The MA Pregnancy to Early Life Longitudinal (PELL) and The MA BSAS Management Information System. The PELL data system is a very comprehensive maternal and child health relational data systems, that longitudinally links all MA birth certificates and fetal death records to their corresponding maternal and infant hospital discharge records for delivery utilization, and then in turn is longitudinally linked with multiple associated reproductive and pediatric programmatic and surveillance datasets, including child and maternal death data; inpatient hospital discharge, emergency department, and outpatient observation stay data; birth defect and cancer registries; early intervention and Special Supplemental Nutrition Program for Women, Infants, and Children program data. PELL contains information on all MA births since 1998, including over 1 000 000 births and 700 000 unique mothers. It has been used in over 30+ peer-reviewed articles to date. The MA Department of Public Health (MDPH) maintains and develops the PELL data system. The public health datasets in the PELL data system are linked together, on a secure restricted computer at MDPH using randomly generated unique identifiers for mothers and children to form a relational data system organized at the individual level. The PELL core linkage consists of live birth certificates and fetal death reports, provided by the MDPH Registry of Vital Records and Statistics, which are annually linked by MDPH to their corresponding birth and delivery in-patient hospital discharge records, provided by the Center for Health Information and Analysis. Over 98% of birth certificates have been linked to corresponding maternal or infant hospital discharge records. The result is the dyadic linkage of the birth and delivery records of the child and mother. Further details about the PELL data system have been described elsewhere. 6, 7 For this study, PELL provides information on birth and clinical conditions at delivery, hospital-based health service utilization, and is the source of several indicators to determine maternal SUD history.
The MA BSAS is the state agency responsible for all SUD prevention, treatment and policy programs in MA. Its Management Information System datasets contain longitudinal treatment records for all women of reproductive age to all who use publicly funded substance abuse treatment facilities in MA, over 25 000 annually. BSAS supports about 90% of all SUD treatment facilities in MA, including detoxification programs, inpatient and residential programs, and methadone clinics. This database provides information about women who have SUDs needs, especially for those women who do not SUD treatment information noted in their hospital based clinical encounters. The BSAS data system provides information on drugs of choice and formal SUD treatments over time; but it has limited information on women's pregnancy and motherhood status. Furthermore, it does not support Alcoholics Anonymous or Driving While Intoxicated programs, and their participants are not included in the BSAS database.
In 2010, through a collaboration of MDPH and Boston University, a multisource multistep linkage algorithm was used to develop a new database linking PELL and BSAS datasets. Details have been previously published. 5, 8 For maternal SUD identification, we used a sex-specific tool/algorithm tested in our prior studies (REF). 9, 10 This new algorithm, the Explicit Mention Substance Abuse need for Treatment (EMSANT) in Women, uses a variety of means to establish maternal SUDs, conceived as a (longitudinal) chronic condition. First and foremost, EMSANT developed a new (International Classification of Diseases, Ninth Revision, Clinical Modification) SUD diagnostic code-based groupers that can be applied to hospital-based administrative discharge data. The EMSANT algorithm is described in detail elsewhere. 9, 10 Mothers were also considered to have SUDs based on birth certificate record mention of a positive toxicology screen, or a record of BSAS treatment within 1 year before delivery. All other women were considered as not having SUDs. Compared with other methods of identifying maternal substance abuse on a population-basis, this algorithm allows for a more robust approach given that it draws upon multiple sources of maternal and infant records. 9, 10 All MA resident mothers who delivered a live-born singleton infant in a MA hospital during 2003-2009 were included in this study (N = 509 548). Mothers were classified as having SUDs or not per the EMSANT algorithm, described above. Infants born to mothers with SUDs were considered "exposed" whereas those born to mothers without SUDs were considered "unexposed. Based upon prior studies, relevant neonatal outcomes of interest included in this study were NAS, preterm birth, low birthweight, neonatal mortality, and intrauterine growth restriction, prolonged hospital stay (>2 days for vaginal births and >4 days for cesarean deliveries) for infants born ≥35 weeks gestational age, neonatal respiratory problems, cardiac problems, feeding/growth difficulties, neurologic abnormalities, infectious conditions, and hematologic problems. Hospitalbased infant care in the first year of life included an episode THE JOURNAL OF PEDIATRICS • www.jpeds.com Volume 191 • December 2017 of rehospitalization after discharge from the birth hospital, observational stays, or emergency department use. If an infant was discharged home after birth hospitalization and then rehospitalized for NAS, then this event was considered a rehospitalization event.
Infants born to mothers with SUDs were considered "exposed" while those born to mothers without SUDs were considered "unexposed." Categories of drugs of abuse included opioids, stimulants, alcohol, hypnotics (excluding alcohol), marijuana and other, which included phencyclidine, other hallucinogens, inhalants, and over-the-counter medications.
Maternal characteristics included age, maternal race/ ethnicity, maternal education, insurance coverage, medical conditions including hypertension, diabetes, and psychiatric diagnoses. We controlled for the following maternal characteristics: maternal age, race/ethnicity, education, marital status, health insurance, parity, smoking during pregnancy, adequacy of prenatal care (defined according to the Kotelchuck index 11 ), psychiatric diagnoses, chronic conditions, pregnancyrelated conditions, delivery complications, and mode of delivery. These measures were selected based upon prior literature that demonstrated associations with SUDs as well as with infant health outcomes.
12-14

Statistical Analyses
We assessed the association of maternal characteristics with the presence or absence of maternal SUD diagnosis; we used c 2 tests with a significance level of P < .05. To assess study aim 1, we developed separate/repeated multivariable logistic regression models to characterize the association of maternal SUDs with each of the study outcome measures. We controlled for the following maternal characteristics: maternal age, race/ethnicity, education, marital status, health insurance, parity, smoking during pregnancy, adequacy of prenatal care, psychiatric diagnoses, chronic conditions, pregnancy-related conditions, delivery complications, and mode of delivery based upon prior bivariate results and prior literature. Given that preterm infants have a higher prevalence of adverse outcomes, we included prematurity in the adjusted models for all neonatal outcomes except preterm birth, NAS, and prolonged hospital stay. For the outcomes of NAS and prolonged hospital stay, we limited our multivariate analysis to infants greater than 35 weeks gestational age.
To assess study aim 2, the association between maternal SUD status and hospital-based care in the first year of life, we developed 3 separate multivariable logistic regression models for each outcome measure, controlling for the following maternal and infant characteristics: maternal age, race/ ethnicity, education, marital status, health insurance, parity, smoking during pregnancy, adequacy of prenatal care, maternal health conditions, psychiatric diagnoses and preterm birth. Generalized estimating equations were used to estimate the differences in characteristics between SUD and non-SUD (reference) groups to account for women who had more than 1 delivery during the 7-year study time period. MDPH Institutional Review Board reviewed and approved this study.
Results
From 2003 to 2009, there were 509 548 singleton live births in MA. Among these mothers, 13 012 (2.6% or 26/1000 births) had SUDs. Moreover, from 2003 to 2009, maternal use of substances in all substance categories increased, particularly for opioids and marijuana ( Table I) .
Compared with mothers without SUDs, mothers with SUDs were more likely to be younger, less educated, unmarried, not privately insured, have more than 2 prior pregnancies, and smoke during pregnancy. White non-Hispanic and black nonHispanic mothers were more likely to have SUDs, whereas Asian non-Hispanic mothers were less likely to have SUDs. In terms of health status and receipt of care, mothers with SUDs were less likely to receive adequate prenatal care, but more likely to have psychiatric, chronic, and pregnancy-related conditions.
Mothers with SUDs were also more likely to suffer delivery complications (Table II) .
Table III presents in its initial columns the unadjusted bivariate analysis of neonatal medical conditions by maternal SUD status (study aim 1). Overall, 8.6% of the singleton infants in the cohort were born preterm and 5.5% were born low birthweight; 1319 (0.26%) of live born neonates died and 4516 (0.9%; 9/1000 births) of all infants were diagnosed with NAS. Neonates born to mothers with SUDs were substantially more likely to be preterm and low birthweight and more likely to suffer all medical complications measured in this study including mortality, NAS, cardiac, respiratory, neurologic, infectious, hematologic, and feeding/nutrition conditions and intrauterine growth restriction, as well as more likely to have prolonged hospital stays (among infants ≥35 weeks).
In the multivariate analysis, adjusting for maternal and infant characteristics, infants born to mothers with SUDs were at significantly greater risk for all neonatal outcomes measured including preterm birth, low birthweight, mortality, NAS, cardiac, respiratory, neurologic, infectious, hematologic, gastrointestinal/nutrition condition, intrauterine growth restriction, and prolonged hospital stay. Table IV presents the unadjusted and adjusted results of hospital-based care use in the first year of life stratified by preterm and term status (study aim 2). In the bivariate analysis, compared with unexposed infants, infants born to SUD mothers had higher use of hospital-based care, including admission, observational stay, and emergency department use. In the multivariate analysis, compared with non-SUD infants, SUD-exposed term infants were more likely to be re-admitted to the hospital but less likely to use the emergency department. †Generalized estimating equations were used to estimate the differences in characteristics between SUD and non-SUD (reference) groups to account for women who had more than 1 delivery during the study time period. Crude analysis limited to those with known data on SUD exposure and characteristics of interest. Adjusted analysis limited to those with known data on SUD exposure and covariates in Table I .
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Discussion
In this robust population-based analysis of maternal SUDs and neonatal and infant outcomes in MA from 2003 to 2010, we demonstrated that exposed infants are at significantly greater risk for adverse outcomes in the immediate perinatal period and for some infants, through the first year of life. Prior literature has demonstrated increased risk for adverse birth outcomes from maternal substance use. Maternal use of opioids, stimulants, alcohol, hypnotics, and marijuana during pregnancy have all been shown, in varying degrees, to increase the risk for preterm birth, low birthweight, neonatal mortality, cardiorespiratory complications, and other medical conditions, as also demonstrated in this study. In recent years, in the wake of the opioid epidemic, there has been a tremendous increase the prevalence of maternal opioid use, both prescribed and illicit, leading to a sharp increase in neonates with NAS. 1, 15, 16 In our cohort, nearly 1% of infants were born to mothers with opioid use disorder and over 60% were diagnosed with NAS. Infants with NAS are more likely to have respiratory, neurologic, infectious, and feeding problems leading to longer lengths of hospital stay. 17 With the legalization of marijuana in several US states, there has been a greater demand for robust research on the effects †Limited analysis to those whose gestational age ≥35 weeks, with known data on mode of delivery and birth hospital records (N = 5705 nonhospital births). ‡Generalized estimating equations were used to estimate the differences in characteristics between SUD and non-SUD (reference) groups to account for women who had more than 1 delivery during the study time period. Crude analysis limited to those with known data on SUD exposure, preterm status and infant outcomes. Adjusted analysis limited to those with known data on SUD exposure, preterm status, infant outcomes, and covariates in Table I . †Generalized estimating equations were used to estimate the differences in characteristics between SUD and non-SUD (reference) groups to account for women who had more than 1 delivery during the study time period. Crude analysis limited to those with known data on SUD exposure, preterm status, and infant outcomes. Adjusted analysis limited to those with known data on SUD exposure, preterm status, infant outcomes and covariates in Table I .
of marijuana on neonatal and infant health. In a recent case control study, investigators reported that prolonged smoking of marijuana during pregnancy was associated with higher rates of spontaneous preterm birth, but not other perinatal conditions such as preeclampsia, gestational diabetes, and smallfor-gestational-age status. 18 Conversely, a recent retrospective cohort study demonstrated no increased risk for adverse perinatal outcomes among mothers who smoked marijuana compared with nonsmokers, but this study was limited by lack of control for quantity and frequency of marijuana use. However, when marijuana was combined with cigarette smoking, infants were more likely to be born preterm and low birthweight. 19 National estimates of stimulant use range from 0.2% for methamphetamine use to 1.5% for cocaine use in the US adult population. Hypnotic use ranges from 0.3% to 1.4% in the adult population. Perinatal outcomes associated with stimulants, particularly cocaine use during pregnancy, include placental abruption, fetal demise, preterm birth, low birthweight, and small-for-gestational-age status. 20 Some infants born to SUD mothers were significantly more likely to be readmitted to the hospital in the first year of life. This finding is consistent with a recently published analysis of hospital readmission rates for NAS infants born in New York State from 2006 to 2009, 21 which found that the adjusted risk for readmission for NAS infants was markedly elevated compared with healthy term infants, with rates similar to that of late preterm infants. The effect estimate for this study of New York State infants was larger than our results (aOR 2.49; 95% CI 1.75-3.55 vs aOR 1.12; 95% CI 1.05-1.20) likely because of differences in exposure. The prior study assessed rehospitalization of infants with the diagnosis of NAS whereas we investigated hospital-based care for all infants exposed to SUDs, a more heterogeneous exposure. Regardless, the precise reasons for this additional hospital-based care are unclear. Although, the perinatal medical complications secondary to in utero exposure are well-known for certain substances like opioids and alcohol, less is known about how these early exposures contribute to additional health problems during infancy and childhood. Furthermore, it is difficult to disentangle the biologic disruptions of in utero exposure from the high-risk social situations that these infants may be born into and whether the mothers or other caregivers for these children were sufficiently engaged during their infants' initial birth hospitalization and subsequently adhered to recommended infant care practices after hospital discharge.
There are several practice and policy implications from our work. First, given that nearly all infants born to SUD mothers were at significantly greater risk for adverse neonatal and infant outcomes compared with non-SUD mothers, mothers should be given appropriate counseling during pregnancy about these risks. With the recent increase in opioid prescriptions as well as the legalization of marijuana in several states, mothers may not be receiving a consistent message about the potential risks of prenatal exposure to their infants. Furthermore, with increased use of these substances in the adult population, providers may not routinely screen all pregnant women and, thus, the degree of information about fetal exposure and potential perinatal risks is minimized or not known. In 2012, the MDPH released guidelines for maternal/newborn screening for alcohol and substance use, highlighting the need for a community standard and consensus approach to screening of pregnant women. 22 Other departments of public health in states like Colorado and Oregon, which legalized marijuana, have released guidelines on how to educate mothers about the risks of adverse infant outcomes associated with use during and after pregnancy. Despite the availability of such guidelines, little is known about the adherence by medical providers to these recommended practices and whether such screening and educational efforts have improved maternal and infant outcomes. Furthermore, data are lacking about receipt of appropriate therapy for SUD mothers and whether treatment lowers the risk for adverse infant outcomes in the neonatal and post-neonatal period. Kotelchuck et al, using the same Massachusetts data sources, but for 2003-2007 only, found that organized SUD treatment (vs no or detox only treatment) for women with SUDs reduced the likelihood of poor birth outcomes/perinatal complications (low birthweight, prematurity, and infant mortality), although the rates of negative perinatal complications were still elevated compared with women without SUDs. 5 Improved surveillance systems may be needed to accurately assess the availability of maternal SUD education, screening, and treatment to invest additional resources efficiently and effectively to implement targeted strategies.
Second, given our study finding that infants born to SUDmothers were more likely to require hospital-based care in the first year of life, additional analyses focused on reasons for readmission or emergency department use are needed. The causes are likely multifactorial and include ongoing medical complications because of fetal exposure to maternal substances as well as disruptive family situations leading to lack of adherence to recommended infant care practices. With the recognition that infants born to SUD mothers may be discharged to more unstable home environments, mothers and other caregivers should be adequately engaged and educated during pregnancy and the birth hospitalization about safe infant care practices. The transition from the birth hospital to home should also be standardized for these infants as for all high-risk neonates as outlined by the American Academy of Pediatrics. 23 Although the American Academy of Pediatrics guidelines do not highlight SUD-exposed infants, it would be reasonable to apply these recommendations given their ongoing medical and social risk after hospital discharge.
There are several limitations to this study. First, although this multisource dataset is a comprehensive resource for analysis of mothers with SUDs and their infants, some women may not be captured from this dataset, such as MA resident women who delivered in hospitals outside of Massachusetts (and hence not in PELL). Also, hospital-based care for MA-born infants who receive medical care outside of the state is not captured. Second, this database does not contain information about MA women with SUDs who received their SUD treatment outof-state or in private facilities that did not have a contractual relationship with the MDPH. Third, poly-drug use by women with SUDs is common, with alcohol being the most widely used THE JOURNAL OF PEDIATRICS • www.jpeds.com Volume 191 with other substances. Although we sought to determine the principal substance of abuse through hospital and emergency records, infant's hospital records and birth certificates, and from reports of "drug of choice" associated with admissions in the BSAS treatment dataset, the frequency and quantity of use of other nonprincipal substances is not known. Thus, it would be nearly impossible to assess the independent association of 1 specific drug with neonatal and infant outcomes. Moreover, we did not control for the mother's type of primary drug, addiction severity, or receipt of appropriate treatment. Fourth, for our analysis of infant utilization of hospitalbased services, we cannot conclude if the need for additional medical care is due to potential persistent biologic effects of in utero exposure to maternal substances or external factors such as lack of access to or timely use of outpatient-based medical homes related to complex social risk of mothers with SUDs. Finally, we also recognize that the data for this study may not be as timely given that the most recent results occurred in 2010. Given the greater restrictions on linkage of more recent data related to substance use within the MDPH, creating a linked dataset for maternal and infant data after 2010, was not possible at this time.
Despite these limitations, this study presents a comprehensive population-based approach to understanding the epidemic risk of maternal SUDs and its effect on the neonate and infant health. This analysis adds an additional 3 years of data to prior studies in Massachusetts and offers new information on neonatal clinical conditions and the need for hospitalbased care in the first year of life for SUDs exposed infants, and offers valuable information to medical providers, public health officials, and maternal and child health researchers about potential areas of improvement in the care of mothers with SUDs and their drug exposed infants. ■
